irbesartan brands
48 registered brands containing irbesartan in Kenya.
Irbesartan
PubChem CID 3749Molecular formula: C25H28N6O
Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland. Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor. Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure. Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure. Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.
Source: PubChem (NCBI) · compound 3749
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| AMLOARB 10 TABLETS IRBESARTAN BP 300MG AND AMLODIPINE (AS BESYLATE) 10.0MG PER TABLET. |
Dawa | Registered | Kenya |
| AMLOARB 5 TABLETS IRBESARTAN 300MG & AMLODIPINE (AS BESYLATE) 5MG PER TABLET. |
Dawa | Registered | Kenya |
| ANDARAN 300MG |
Sandoz | Registered | Kenya |
| ANDARAN 150MG |
Sandoz | Registered | Kenya |
| ANDARAN 75MG |
Sandoz | Registered | Kenya |
| ANDARAN HCT 300MG/12.5MG |
Nvs Kenya | - | Kenya |
| ANDARAN HCT 150MG/12.5MG |
Nvs Kenya | Withdrawn | Kenya |
| APROVASC 150MG/10MG TABLET 150MG / 10MG |
Ressourcethica | Registered | Kenya |
| APROVASC 150MG/5MG TABLET 150MG/5MG |
Ressourcethica | Registered | Kenya |
| APROVASC 300MG/10MG TABLET IRBESARTAN / AMLODIPINE BESYLATE |
Ressourcethica | Registered | Kenya |
| APROVASC 300MG/5MG TABLET 300MG / 5MG |
Ressourcethica | Registered | Kenya |
| APROVEL 150MG TABLET 150MG |
Ressourcethica | Registered | Kenya |
| Aprovel 150mg tablet Tablet |
Sanofi-aventis Kenya | Retained | Kenya |
| APROVEL 300MG TABLET 300MG |
Ressourcethica | Registered | Kenya |
| ARBI 150MG TABLET IRBESARTAN 150 MG |
Harleys | Registered | Kenya |
| ARBI 300MG TABLET IRBESARTAN 300 MG |
Harleys | Registered | Kenya |
| ARBI-D 150/12.5MG TABLET IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG |
Harleys | Registered | Kenya |
| CO-APROVEL 150MG/12.5MG TABLET IRBESARTAN 150MG + HYDROCHLOROTHIAZIDE 12.5MG |
Ressourcethica | Registered | Kenya |
| CO-APROVEL 300MG/12.5MG TABLET IRBESARTAN 300MG + HYDROCHLOROTHIAZIDE 12.5MG |
Ressourcethica | Registered | Kenya |
| CO-APROVEL 300MG/25MG TABLET IRBESARTAN 300MG + HYDROCHLOROTHIAZIDE 25MG |
Ressourcethica | Registered | Kenya |
| CONVERIUM 150G IRBERSARTAN 150MG |
Sunpar Pharmaceuticals | Registered | Kenya |
| CONVERIUM 300MG IRBESARTAN 300MG |
Sunpar Pharmaceuticals | Registered | Kenya |
| CORYCARDON 150/12.5MG TABLETS 150/12.5MG |
Europa Healthcare | Registered | Kenya |
| CORYCARDON 300/12.5MG TABLETS 300/12.5MG |
Europa Healthcare | Registered | Kenya |
| IRBETAN 150 IRBESARTAN USP 150MG |
Surgilinks | Registered | Kenya |
| IRBETAN 300 IRBESARTAN USP 300MG |
Surgilinks | Registered | Kenya |
| IRBETAN-H IRBESARTAN USP 150 MG & HYDROCHLOROTHIAZIDE BP12.5 MG |
Surgilinks | Registered | Kenya |
| IRBIS 150 EACH FILM COATED TABLET CONTAINS 150 MG OF IRBESARTAN PH.EUR |
Unisel | Registered | Kenya |
| IRBIS 300 EACH FILM COATED TABLET CONTAINS 300 MG OF IRBESARTAN PH.EUR |
Unisel | Registered | Kenya |
| IRBIS 75 EACH FILM COATED TABLET CONTAINS 75 MG OF IRBESARTAN PH.EUR |
Unisel | Registered | Kenya |
| IRBIS-HT 150/12.5 IRBESARTAN PH.EUR 150 MG, HYDROCHLOROTHIAZIDE PH.EUR 12.5 MG |
Unisel | Registered | Kenya |
| IRBIS-HT 300/12.5 IRBESARTAN 300 MG AND HYDROCHLOROTHIAZIDE 12.5 MG |
Unisel | Registered | Kenya |
| IROVEL 150MG TABLETS 150 MG |
Sun Pharma | Registered | Kenya |
| IROVEL 150MG TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| IROVEL 150MG TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| IROVEL 300MG TABLETS 300 MG |
Sun Pharma | Registered | Kenya |
| IROVEL 300MG TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| IROVEL 300MG TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| IROVEL H TABLETS IRBESARTAN - 150 MG HYDROCHLOROTHIAZIDE - 12.5 MG |
Sun Pharma | Registered | Kenya |
| IROVEL H TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| IROVEL H TABLETS Tablet |
Sun Pharmaceutical Industries Limited | Retained | Kenya |
| MEDISART H TABLETS IRBESARTAN USP 150MGS HYDROCHLOROTHIAZIDE 12.5MGS |
Medistar Pharmaceuticals | Registered | Kenya |
| MEDISART TABLETS 150MG |
Medistar Pharmaceuticals | Registered | Kenya |
| RYCARDON 150MG TABLETS 150MG |
Europa Healthcare | Registered | Kenya |
| RYCARDON 300MG TABLETS 300MG |
Europa Healthcare | Registered | Kenya |
| VIVAZAC® 300MG F/C TABLETS EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 300MG |
Evka Consultz | Registered | Kenya |
| VIVAZAC® PLUS (150/12.5) MG F/C TABLETS EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 150MG AND HYDROCHLOROTHIAZIDE PH EUR 12.5MG |
Evka Consultz | Registered | Kenya |
| VIVAZAC® PLUS (300/25) MG F/C TABLETS EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 300MG AND HYDROCHLOROTHIAZIDE PH EUR 25MG |
Evka Consultz | Registered | Kenya |